GEN Exclusives

More »

GEN News Highlights

More »
Mar 19, 2007

Evotec, Boehringer Ingelheim, and IMP Form Alzheimer’s Disease Target Discovery Collaboration

  • Evotec, Boehringer  Ingelheim, and the Research Institute of Molecular Pathology in Vienna (IMP) will jointly identify novel targets as potential points of intervention in the treatment of Alzheimer’s disease (AD).

    Evotec scientists together with the IMP will apply validated disease models to identify novel AD targets. Based on these models, Boehringer Ingelheim will select and further validate target candidates for its in-house drug discovery program.

    The contract includes an option for Evotec to support Boehringer Ingelheim (BI) in the target validation process. Evotec could then be eligible for milestone payments of up to Euro 20 million plus royalties.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?